转录组网络分析揭示类风湿关节炎患者抗TNF生物制剂应答的关键驱动因素
该研究利用两个独立RA队列(韩国和高加索人群)外周血RNA测序数据,比较抗TNF生物制剂初始治疗前后高可靠优应答者与无应答者之间的表达变化,识别出305个应答相关基因,其中41个为四个应答相关网络的关键驱动基因,并开发转录组应答评分,该评分与独立中等或模糊应答患者的临床指标变化显著相关。
要点
- 抗TNF治疗诱导表达变化在优应答者与无应答者间有305个基因显著不同。
- 41个应答相关基因作为关键驱动基因参与I型IFN、髓系白细胞活化、B细胞活化及NK细胞/淋巴细胞介导的细胞毒性网络。
- 所开发的转录组应答评分与独立中等或模糊应答患者的临床指标变化显著相关。
核心结论
- 在基因和网络水平比较优应答与无应答者,提供了抗TNF药物应答特异性的治疗诱导转录组特征。
研究设计与样本
- 利用两个独立RA队列(韩国和高加索人群)外周血细胞样本,在抗TNF生物制剂初始治疗前后进行RNA测序分析,比较优应答者与无应答者之间治疗诱导的表达变化。
主要发现
- 共305个应答相关基因在优应答者与无应答者之间治疗诱导的表达变化显著不同。
- 共表达网络构建及关键驱动分析显示41个应答相关基因作为四个应答相关网络的关键驱动基因,涉及I型IFN信号、髓系白细胞活化、B细胞活化及NK细胞/淋巴细胞介导的细胞毒性通路。
- 所开发的转录组应答评分用于估计个体水平应答相关关键驱动基因的表达变化程度,在独立中等或模糊应答患者中与临床指标变化显著相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Anti-TNF biologics have been widely used to ameliorate disease activity in patients with RA. However, a large fraction of patients show a poor response to these agents. Moreover, no clinically applicable predictive biomarkers have been established. This study aimed to identify response-associated biomarkers using longitudinal transcriptomic data in two independent RA cohorts. METHODS: RNA sequencing data from peripheral blood cell samples of Korean and Caucasian RA cohorts before and after initial treatment with anti-TNF biologics were analysed to assess treatment-induced expression changes that differed between highly reliable excellent responders and null responders. Weighted correlation network, immune cell composition, and key driver analyses were performed to understand response-associated transcriptomic networks and cell types and their correlation with disease activity indices. RESULTS: In total, 305 response-associated genes showed significantly different treatment-induced expression changes between excellent and null responders. Co-expression network construction and subsequent key driver analysis revealed that 41 response-associated genes played a crucial role as key drivers of transcriptomic alteration in four response-associated networks involved in various immune pathways: type I IFN signalling, myeloid leucocyte activation, B cell activation, and NK cell/lymphocyte-mediated cytotoxicity. Transcriptomic response scores that we developed to estimate the individual-level degree of expression changes in the response-associated key driver genes were significantly correlated with the changes in clinical indices in independent patients with moderate or ambiguous response outcomes. CONCLUSION: This study provides response-specific treatment-induced transcriptomic signatures by comparing the transcriptomic landscape between patients with excellent and null responses to anti-TNF drugs at both gene and network levels.
引用
- Yu CY, Lee HS, Joo YB, et al. Transcriptomic network analysis reveals key drivers of response to anti-TNF biologics in patients with rheumatoid arthritis. Rheumatology (Oxford). 2024. PMID: 37572297. doi:10.1093/rheumatology/kead403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。